Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI (IRON-RLS)

11 september 2026 bijgewerkt door: University Hospital, Montpellier

Intravenous Iron in the Management of Drug-resistant Restless Legs Syndrome: a Randomized Controlled Delayed-start Trial. IRON-RLS

The pathophysiology of restless legs syndrome (RLS) is not well understood: it is thought to involve intracerebral iron deficiency and dopaminergic dysregulation.

This study aims to evaluate the use of intravenous ferric carboxymaltose in patients with restless legs syndrome (RLS).

This study plans to include individuals with RLS, who will be divided into two groups:

  • One group will receive intravenous iron immediately after the baseline polysomnography
  • The second group will receive intravenous iron 3 months after randomization. In total, participants will be followed for 6 months, during which time they will be required to complete questionnaires regularly, undergo blood draws, and have two polysomnography tests.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

66

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Age ≥ 18 years;
  • Weight ≥ 50 kg;
  • Drug-resistant RLS;
  • Severe to very severe RLS (IRLSSG-Q score > 20), persistent or recurrent for more than one month;
  • Treatment with dopamine agonists without exceeding the recommended doses (ropinirole ≤ 2 mg/day, pramipexole ≤ 0.54 mg/day, rotigotine ≤ 3 mg/day);
  • Treatment with dopamine agonists and/or α2δ ligands and/or opioids that has been stable for at least 3 months;
  • In cases of sleep apnea syndrome, treatment with continuous positive airway pressure (CPAP);
  • Participants were required to be fluent in spoken and written French, be enrolled in a health insurance plan, agree to the automated processing of anonymized confidential data, and have provided written, informed consent for the study.

Exclusion Criteria:

  • Iron supplementation (oral or intravenous) within 3 months prior to enrollment and throughout the study period
  • Serum ferritin < 50 µg/L or > 300 µg/L;
  • Transferrin saturation < 20% or > 45%;
  • Hemochromatosis;
  • RLS augmentation syndrome ;
  • Treatment with neuroleptics or antidepressants;
  • Allergy to iron;
  • Severe infectious or inflammatory disease within the past 3 months;
  • RLS associated with chronic kidney disease, pregnancy, or a clinically significant neurological or psychiatric disorder;
  • Severe sleep apnea syndrome (AHI > 30/h) that is untreated, or in cases where treatment is refused or has failed;
  • Known allergy, inflammatory, or immune disorder;
  • History of severe asthma, eczema, or any other atopic allergy;
  • Pregnancy or breastfeeding;
  • Also excluded are patients participating in another research study, those deprived of their liberty by judicial or administrative order, those living in a medical facility, those subject to a legal protection order, or those from whom consent could not be obtained.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Immediate treatment
The treatment will be administered at at baseline (V1), immediately after the baseline polysomnography
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age
Actieve vergelijker: Delayed-onset treatment
The treatment will be administered at 12 weeks
administration of 1 g of CMF for 2 hours under medical monitoring
Administration of 1 g of CMF for 2 hours under medical monitoring
Randomization in the arm "Immediate treatment" or "Delayed-onset treatment"
Completion of questionnaires and scales: European Quality of Life 5 Dimensions (EQ-5D), Epworth Sleepiness Scale (ESS), Clinical Global Impression (CGI), Patient Global Impression (PGI), Beck Depression Inventory-II (BDI-II), Augmentation Severity Rating Scale (ASRS), International Restless Legs Study Group Severity Rating Scale (IRLSSG-Q), International Restless Legs Syndrome (IRLS), Insomnia Severity Index (ISI)
Lumbar puncture performed according to standard practice
During inclusion visit (Day 0) only for women of childbearing age

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
IRLSSG-Q score
Tijdsspanne: From Day 0 to Week 12
IRLSSG-Q : International Restless Legs Study Group Severity Rating Scale allows for the quantification of the severity of restless legs syndrome
From Day 0 to Week 12

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Periodic Limb Movements during Sleep (PLMS) index
Tijdsspanne: From V1 (Day 0) to V5 (week 24)
The PLMS Index measures the average number of involuntary leg movements per hour of sleeping during polysomnography. 15 or more per hour: Considered abnormal for adults and may suggest a condition called Periodic Limb Movement Disorder (PLMD) if it disrupts your sleep.
From V1 (Day 0) to V5 (week 24)
Total sleep time
Tijdsspanne: From day 0 to week 24
Total sleep time measured in minutes during polysomnography.
From day 0 to week 24
Sleep latency
Tijdsspanne: From Day 0 to week 24
Length of time in minutes it takes to transition from full wakefulness to the lightest stage of sleep after the lights are turned off.
From Day 0 to week 24
Sleep time at stage 1-2 during polysomnography
Tijdsspanne: From Day 0 to week 24
Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography
From Day 0 to week 24
Sleep time at stage 3 during polysomnography
Tijdsspanne: From Day 0 to week 24
Time spent in stage 3 sleep measured in hours and minutes during polysomnography
From Day 0 to week 24
Micro-awakenings index (MAI)
Tijdsspanne: From Day 0 to week 24
The Micro-awakenings index measures the number of brief awakenings that the person does not notice per hour of sleep.
From Day 0 to week 24
Apnea-hypopnea index (AHI)
Tijdsspanne: From Day 0 to week 24
The apnea-hypopnea index (AHI) measures the average number of interruptions or reductions in breathing per hour of sleep to assess the severity of sleep apnea.
From Day 0 to week 24
Average arterial oxygen saturation (SaO2)
Tijdsspanne: From Day 0 to Week 24
The unit of measurement for SaO2 is the percentage (%).
From Day 0 to Week 24
Oxygen desaturation index (IDO)
Tijdsspanne: From Day 0 to week 24
The oxygen desaturation index (IDO) measures the number of significant drops in blood oxygen levels per hour of sleep.
From Day 0 to week 24
Serum ferritin
Tijdsspanne: From Day 0 to week 24
From Day 0 to week 24
Transferrin saturation coefficient
Tijdsspanne: From Day 0 to Week 24
From Day 0 to Week 24
Epworth Sleepiness Scale (ESS)
Tijdsspanne: From Day 0 to Week 24
A measure of excessive daytime sleepiness that quantifies the impact of the condition on alertness throughout the day. Eight everyday situations are rated (for example, watching television, riding as a passenger in a car, sitting quietly in a public place). Each situation is scored from 0 to 3 based on the likelihood of falling asleep. Total score 0-24; a score of ≥10 suggests excessive sleepiness
From Day 0 to Week 24
European Quality of Life 5 Dimensions (EQ-5D)
Tijdsspanne: From Day 0 to Week 24
EQ-5D: this self-administered questionnaire assesses five dimensions (mobility, daily activities, self-care, pain/discomfort, anxiety/depression) as well as overall health status on a visual scale from 0 to 100
From Day 0 to Week 24
Clinical Global Impression (CGI)
Tijdsspanne: From Day 0 to Week 24
The clinician's overall assessment of the illness, including CGI-S (severity) and CGI-I (change). 7-point scale: CGI-S 1 = normal, 7 = extremely ill; CGI-I 1 = markedly improved, 7 = markedly worsened
From Day 0 to Week 24
Patient Global Impression (PGI)
Tijdsspanne: From Day 0 to Week 24
Patient's overall perception of the severity of their illness or change; a simple 7-point scale, self-reported. A high score is associated with patients perceiving their symptoms as severe
From Day 0 to Week 24
Beck Depression Inventory-II (BDI-II)
Tijdsspanne: From Day 0 to Week 24
BDI-II: a self-administered questionnaire consisting of 21 items that assess the severity of depressive symptoms over the past two weeks; score range: 0-63; thresholds: 0-13 (mild), 14-19 (moderate), 20-28 (severe), ≥29 (severe)
From Day 0 to Week 24
Augmentation Severity Rating Scale (ASRS)
Tijdsspanne: From Day 0 to Week 24
A 7-item self-administered questionnaire used to quantify the severity of the augmentation syndrome in patients treated with dopamine agonists. It assesses the worsening or early onset of RLS symptoms and their impact on sleep and daily activities
From Day 0 to Week 24
Insomnia Severity Index (ISI)
Tijdsspanne: From Day 0 to week 24
To assess the severity of the patient's insomnia, taking into account both the quantity and quality of sleep, as well as its impact on daily functioning (fatigue, concentration, mood). A 7-item self-report questionnaire scored from 0 to 4, with a total score of 0-28; 0-7 indicates no insomnia, 8-14 mild, 15-21 moderate, and 22-28 severe insomnia
From Day 0 to week 24

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 oktober 2026

Primaire voltooiing (Geschat)

1 april 2029

Studie voltooiing (Geschat)

1 oktober 2030

Studieregistratiedata

Eerst ingediend

28 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 september 2026

Eerst geplaatst (Werkelijk)

16 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 september 2026

Laatste update ingediend die voldeed aan QC-criteria

11 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren